Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1648 1671 1672
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18360190 | Glycoengineered protein nanoparticles and uses thereof | Non-Final OA | University of Washington |
| 18250779 | REPLICATION-DEFECTIVE VACCINES AND USES THEREOF | Non-Final OA | Rutgers, The State University of New Jersey |
| 18549134 | COMPOSITIONS, KITS, AND METHODS FOR VARIANT-RESISTANT DETECTION OF TARGET VIRAL SEQUENCES | Non-Final OA | LIFE TECHNOLOGIES CORPORATION |
| 18276905 | INFLUENZA VACCINE COMPOSITIONS AND METHODS OF USING SAME | Non-Final OA | Children's Hospital Medical Center |
| 18255308 | COMPOSITIONS AND METHODS FOR DIAGNOSING SARS-COV-2 (COVID-19) AND FOR MONITORING SARS-COV-2-SPECIFIC IMMUNOLOGICAL MEMORY | Non-Final OA | QIAGEN SCIENCES LLC |
| 18283601 | IMMUNOGENIC COMPOSITIONS | Non-Final OA | CUREVAC SE |
| 18020659 | PROTEINS, POLYNUCLEOTIDES, AND METHODS FOR TREATING CORONAVIRUS INFECTION | Final Rejection | WESTPORT BIO, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy